We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Brown Rice Can Be Used to Make Artificial Albumin

By LabMedica International staff writers
Posted on 03 Jan 2012
A new study claims that rice can be used to make recombinant human serum albumin (HSA), a protein found in human blood that is often used for treating burns, traumatic shock, and liver disease.

Researchers at Wuhan University (China), the National Research Council of Canada (Ottawa), and the Center for Functional Genomics (Albany, NY, USA) introduced recombinant HSA protein promoters into brown rice plants of the genus Oryza sativa, commonly known as Asian rice. More...
Using Agrobacterium, they developed 25 transgenic plants, nine of which were able to breed. The researchers then succeeded in producing recombinant (HSA) (OsrHSA) from the transgenic rice, with levels reaching 10.58% of the total soluble protein of the rice grain. Physical and biochemical characterization of the OsrHSA revealed it to be equivalent to plasma-derived HSA (pHSA).

Furthermore, in murine models, the efficiency of OsrHSA in promoting cell growth and treating liver cirrhosis was similar to that of pHSA, as well as displaying similar in vitro and in vivo immunogenicity. According to the researchers, the results suggest that a rice seed bioreactor could produce cost-effective recombinant HSA that is safe and could help satisfy an increasing worldwide demand for HSA. Large-scale production of OsrHSA with a purity of over 99% could be consistently done, with a productivity rate of 2.75 grams of albumin per one kilogram of brown rice. The study was published in the November 22, 2011, issue of the Proceeding of the National Academy of Sciences (PNAS).

“Our results suggest that a rice seed bioreactor produces cost-effective recombinant HSA that is safe and can help to satisfy an increasing worldwide demand for human serum albumin,” concluded lead author Yang He, PhD, and colleagues of the Engineering Research Center for Plant Biotechnology and Germplasm Utilization. “More research is needed to evaluate the safety of the rice-derived protein in animals and humans before it can be considered for the market.”

HSA is widely used in clinical and cell culture applications, including the manufacture of vaccines and drugs. The worldwide demand for the blood protein is about 500 tons per year, and China has faced worrying shortages in the past, since conventional production of HSA from human blood is limited by the availability of blood donation. Concerns have also been raised about the potential for the transmission of hepatitis and HIV, since the protein comes from human blood, with a high risk of viral transmission from donors.

Related Links:

Wuhan University
National Research Council of Canada
Center for Functional Genomics



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Pipette Controller
Sapphire MaxiPette
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.